Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003

被引：0

作者：

Tan, Wei Shen ^{[1
,2
,4
]}

Kelly, John D. ^{[1
,3
]}

HIVEC-II Trial Team ^{[1
]}

机构：

[1] UCL, Div Surg & Intervent Sci, London, England

[2] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX USA

[3] Univ Coll London Hosp, Dept Urol, London, England

[4] UCL, Div Surg & Intervent Sci, 43-45 Foley St, London W1W 7TY, England

来源：

EUROPEAN UROLOGY | 2023年 / 83卷 / 01期

关键词：

MITOMYCIN-C; HYPERTHERMIA; EFFICACY;

D O I：

10.1016/j.eururo.2022.10.009

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E29 / E30

页数：2

共 12 条

[1] Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press.
Sahoo, Suman
Pandey, Abhishek
Mandal, Swarnendu
Das, Manoj Kumar
Nayak, Prasant
[J]. EUROPEAN UROLOGY, 2023, 83 (02) : E47 - E47
[2] Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo. 2022.08.003
Tan, Wei Shen
Mustard, Connor
Kelly, John D.
[J]. EUROPEAN UROLOGY, 2023, 83 (02) : E48 - E49
[3] Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press.
Campodonico, Fabio
Mattioli, Francesca
Introini, Carlo
[J]. EUROPEAN UROLOGY, 2023, 83 (02) : E56 - E57
[4] Re: Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial
Paolo, Gontero
Francesco, Soria
[J]. EUROPEAN UROLOGY, 2023, 83 (06) : 580 - 580
[5] Letter to the Editor Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010
Montorsi, Francesco
Rosiello, Giuseppe
Gandaglia, Giorgio
Salonia, Andrea
Briganti, Alberto
[J]. EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03):
[6] Re: Marc-Oliver Grimm, Antione G. van der Heijden, Marc Colombel, et al. Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.066
Karabay, Emre
Tinay, Ilker
[J]. EUROPEAN UROLOGY, 2020, 78 (04) : E161 - E162
[7] Reply to Emre Karabay and Ilker Tinay's Letter to the Editor re: Treatment of High-grade Non-muscle-inva- sive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.066
Grimm, Marc-Oliver
Caris, Christien
Witjes, Wim P. J.
[J]. EUROPEAN UROLOGY, 2020, 78 (04) : E163 - E164
[8] Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh's Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j. eururo.2024.02.016
Garcia-Ruiz, Alonso
Macarro, Carlos
Mateo, Joaquin
Perez-Lopez, Raquel
[J]. EUROPEAN UROLOGY, 2024, 86 (03) : e69 - e70
[9] Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell EN Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016
Becker, Russell E. N.
Baras, Alex
Bivalacqua, Trinity J.
[J]. EUROPEAN UROLOGY, 2021, 79 (02) : E58 - E59
[10] Reply to Kirti Singh, Swarnendu Mandal, Manoj Kumar Das, Prasant Nayak, and Sambit Tripathy's Letter to the Editor re: Andreas Hiester, Yue Che, Achim Lusch, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.10.021
Che, Yue
Hiester, Andreas
Albers, Peter
[J]. EUROPEAN UROLOGY, 2023, 83 (06)

← 1 2 →